Literature DB >> 3598320

Faecal occult blood screening of first degree relatives of patients with colorectal cancer.

N C Armitage, P A Farrands, C M Mangham, J D Hardcastle.   

Abstract

A full first-degree family history was taken from 161 patients with colorectal cancer (Group 1) and from a group of 203 subjects previously investigated and found to have no colorectal neoplasia (Group 2). Twenty-six (16%) of patients in Group 1 compared with 23 (11%) in Group 2 had at least 1 first-degree relative with colorectal cancer (p = 0.23). Contact of first-degree relatives was possible in 123 patients in Group 1. Of these, 4 were members of 'cancer families' with 26 available first-degree relatives. The remaining 119 patients had 341 contactable first-degree relatives. They were approached by post and offered faecal occult blood (FOB) screening. One hundred and sixty-two (47%) completed FOB tests of which 12 (8%) were positive. Investigation of these individuals detected 4 adenomas. In the subgroup of 20 patients with 1 or 2 first-degree relatives with colorectal cancer, there were 78 potential relatives of whom 71 were contacted. Thirty-two (45%) FOB tests yielded 1 positive found to have an adenoma. A control group of 332 individuals was selected randomly from general practitioners' lists and offered FOB testing. One hundred and fifty-five (47%) complied of whom 7 (4.5%) were positive. Investigation yielded 1 adenoma. Thirteen of the 26 relatives of the 4 'cancer family' patients were investigated by endoscopy and 2 (15%) had large polyps detected. Although there may be an increased risk of colorectal neoplasia in first-degree relatives of patients with sporadic colorectal cancer, this risk is not sufficiently high to justify separate screening.

Entities:  

Mesh:

Year:  1986        PMID: 3598320     DOI: 10.1007/bf01648347

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  6 in total

1.  A control trial of faecal occult blood screening for colorectal cancer: 2-year results.

Authors:  J D Hardcastle; N C Armitage; J Chamberlain; T W Balfour; S S Amar
Journal:  Br J Surg       Date:  1985-09       Impact factor: 6.939

2.  Surveillance/management of an obligate gene carrier: the cancer family syndrome.

Authors:  H T Lynch; W A Albano; T A Ruma; G D Schmitz; K A Costello; J F Lynch
Journal:  Gastroenterology       Date:  1983-02       Impact factor: 22.682

3.  Family studies in cancer of the colon and rectum.

Authors:  E Lovett
Journal:  Br J Surg       Date:  1976-01       Impact factor: 6.939

4.  Colonoscopy in asymptomatic individuals with a family history of colorectal cancer.

Authors:  R R Love; J F Morrissey
Journal:  Arch Intern Med       Date:  1984-11

5.  Family incidence of carcinoma of the colon and rectum in north-east Scotland.

Authors:  J L Duncan; J Kyle
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

6.  A comparison of an immunological faecal occult blood test Fecatwin sensitive/FECA EIA with Haemoccult in population screening for colorectal cancer.

Authors:  N Armitage; J D Hardcastle; S S Amar; T W Balfour; J Haynes; P D James
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

  6 in total
  1 in total

Review 1.  Colorectal carcinoma and Haemoccult. A study of its value in mass screening using meta-analysis.

Authors:  J Windeler; J Köbberling
Journal:  Int J Colorectal Dis       Date:  1987-11       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.